AD109 Phase 3 Study Results Unveiled at CHEST Annual Meeting
- Topline findings from the pivotal Phase 3 studies, SynAIRgy and LunAIRo, reveal that AD109 significantly reduced the apnea-hypopnea index (AHI) over 26 weeks, meeting primary endpoints in both trials. The results also indicated consistent improvements in important secondary measures related to oxygenation, including the oxygen desaturation index (ODI3) and hypoxic burden (HB4).
- These results bolster the understanding of how AD109, a once-nightly investigational oral medication, addresses the neuromuscular causes of obstructive sleep apnea (OSA) and the related oxygen deficiencies.
- The findings validate previous positive topline data and highlight AD109's potential to revolutionize OSA treatment as Apnimed moves toward its planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration.
Key Insights from the Additional Data
Recent information indicates that both the SynAIRgy and LunAIRo studies successfully achieved their primary endpoint, a reduction in apnea-hypopnea index (AHI) at the 26-week mark. Notably, AD109 provided clinically relevant enhancements in oxygenation, showcasing significant reductions in both the oxygen desaturation index (ODI3) and hypoxic burden (HB4) when compared to a placebo. These findings emphasize AD109's capability to tackle the neuromuscular dysfunction and oxygenation deficits prevalent in OSA, underlining its potential to reshape OSA treatment—a condition affecting over 80 million people in the U.S. alone.
Dr. Larry Miller, M.D., CEO of Apnimed, commented, "The consistency of these findings underscores our long-held belief that restoring oxygenation is essential for individuals suffering from OSA. As we approach our NDA submission, we are not only underscoring the strength of our scientific foundation but also establishing the groundwork to offer AD109 as an innovative oral remedy for individuals who struggle with existing therapies. Our ambition is to broaden the spectrum of effective treatments, helping more OSA patients discover a suitable solution."
Details from SynAIRgy and LunAIRo Phase 3 Trials
SynAIRgy Phase 3 Results
In the modified intention-to-treat (mITT) population, AD109 exhibited a significant 55.6% mean reduction in AHI from baseline (p<0.0001) compared to 19.1% for placebo (p<0.0001) at 26 weeks. Additionally, the trial demonstrated improvements in key secondary measures:
- Mean reductions in HB4 by 60.5% (p<0.0001) and ODI3 by 44.8% (p<0.0001).
- 39.6% of participants exhibited AHI reductions of 50% or more (p<0.0001).
- 51.2% of participants showed improvements in OSA severity classifications.
- 22.3% achieved complete OSA control (AHI <5 events/hour).
- AD109 was generally well-tolerated with side effects such as dry mouth, insomnia, and nausea; no serious treatment-related adverse events were reported.
LunAIRo Phase 3 Results
Similarly, in the mITT population of the LunAIRo study, AD109 led to a significant 46.8% AHI reduction from baseline (p<0.001) compared to a 6.8% reduction in the placebo group (p<0.001) at 26 weeks. Key findings include:
- Improvements in oxygenation with HB4 reduced by 58.2% (p<0.0001) and ODI3 reduced by 40.3% (p<0.001).
- 38.3% of subjects saw AHI reductions of 50% or more (p<0.0001).
- 45.0% of subjects experienced a decline in OSA severity classification.
- 22.9% achieved full OSA control (defined as AHI <5 events/hour).
- AD109 was also well-received with the most common adverse effects mirroring those seen in the SynAIRgy study.
Dr. Patrick J. Strollo, Jr., MD, who led the SynAIRgy clinical trial, stated, "The notable improvements in oxygenation—an essential biomarker of protection during sleep—are particularly encouraging. Together with previously reported AHI reductions, the new data reinforces AD109's robustness and indicates that, pending approval, it could offer a fresh approach to OSA management by targeting the physiological burden of the illness."
Understanding the Significance of AD109
AD109 is poised to become the first medical treatment aimed at enhancing oxygenation during sleep by directly addressing the neuromuscular factors leading to upper airway collapse in those affected by obstructive sleep apnea. As a novel neuromuscular modulator, AD109 combines aroxybutynin, an innovative antimuscarinic agent, with atomoxetine, a selective norepinephrine reuptake inhibitor. The unique combination targets the fundamental issues behind OSA and emphasizes a simplified treatment approach.
Obstructive sleep apnea is a chronic disorder where the airway collapses during sleep, resulting in intermittent oxygen deprivation. It affects individuals from various demographics, and a significant number remain undiagnosed. This condition not only leads to discomfort during the night but increases the risk of serious long-term health ailments.
About Apnimed's Commitment
Apnimed, headquartered in Cambridge, Massachusetts, is a clinical-stage pharmaceutical firm committed to redefining treatment options for sleep-related breathing diseases. With a vision that centers on the necessity for novel, once-nightly oral therapies, Apnimed aims to broaden the scope of diagnosis and treatment for OSA. The company is developing an array of oral product candidates designed to enhance oxygenation for individuals with OSA.
Frequently Asked Questions
What is AD109 and its purpose?
AD109 is an investigational oral medication designed to treat obstructive sleep apnea by addressing its root neuromuscular causes while improving oxygenation quality during sleep.
What were the significant findings from the Phase 3 trials?
Phase 3 trials revealed significant reductions in the apnea-hypopnea index (AHI) and improvements in oxygen saturation indices, demonstrating AD109's effectiveness compared to placebo.
How is AD109 taken?
The medication AD109 is a once-nightly oral pill intended to be taken at bedtime, simplifying the treatment process for individuals with obstructive sleep apnea.
What patient group was involved in the trials?
The trials involved diverse adult participants with obstructive sleep apnea who had difficulty tolerating continuous positive airway pressure (CPAP) therapy.
What is the future direction for Apnimed and AD109?
Apnimed is preparing for a New Drug Application (NDA) submission to gain approval for AD109, aiming to offer a novel treatment alternative for individuals with OSA.
